Dual PPARα/γ agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice
article
OBJECTIVE - We investigated whether the dual PPARα/γ agonist tesaglitazar has anti-atherogenic effects in ApoE*3Leiden mice with reduced insulin sensitivity. METHODS AND RESULTS - ApoE*3Leiden transgenic mice were fed a high-fat (HF) insulin-resistance-inducing diet. One group received a high-cholesterol (HC) supplement (1% wt/wt; HC group). A second group received the same HC supplement along with tesaglitazar (T) 0.5 μmol/kg diet (T group). A third (control) group received a low-cholesterol (LC) supplement (0.1% wt/wt; LC group). Tesaglitazar decreased plasma cholesterol by 20% compared with the HC group; cholesterol levels were similar in the T and LC groups. Compared with the HC group, tesaglitazar caused a 92% reduction in atherosclerosis, whereas a 56% reduction was seen in the cholesterol-matched LC group. Furthermore, tesaglitazar treatment significantly reduced lesion number beyond that expected from cholesterol lowering and induced a shift to less severe lesions. Concomitantly, tesaglitazar reduced macrophage-rich and collagen areas. In addition, tesaglitazar reduced inflammatory markers, including plasma SAA levels, the number of adhering monocytes, and nuclear factor κB-activity in the vessel wall. CONCLUSIONS - Tesaglitazar has anti-atherosclerotic effects in the mouse model that go beyond plasma cholesterol lowering, possibly caused by a combination of altered lipoprotein profiles and anti-inflammatory vascular effects. © 2006 American Heart Association, Inc. Chemicals / CAS: cholesterol, 57-88-5; collagen, 9007-34-5; tesaglitazar, 251565-85-2; lipid, 66455-18-3; peroxisome proliferator activated receptor alpha, 147258-70-6; 2-ethoxy-3-(4-((4-(methylsulfonyloxy)phenethyl)oxy)phenyl)propanoic acid; Alkanesulfonates; apolipoprotein E3 (Leidein); Apolipoprotein E3; Apolipoproteins E; Biological Markers; Cholesterol, 57-88-5; Cholesterol, Dietary; Collagen, 9007-34-5; Dietary Fats; Lipids; Lipoproteins; NF-kappa B; Phenylpropionates; PPAR alpha; PPAR gamma
Topics
CholesterolInhibitorsCollagenImmunoglobulin enhancer binding proteinSerum amyloid ATesaglitazar2 ethoxy 3 (4 ((4 (methylsulfonyloxy)phenethyl)oxy)phenyl)propanoic acidAlkanesulfonic acidApolipoprotein E3 (Leidein)Biological markerLipoproteinPeroxisome proliferator activated receptor alphaPeroxisome proliferator activated receptor gammaPhenylpropionic acid derivativeAnimal cellAnimal experimentAnimal modelAnimal tissueBlood vessel wallCholesterol blood levelControlled studyDietEnzyme activityMonocyteMouseNonhumanProtein blood levelTransgenic mouseBloodCholesterol intakeDrug potentiationFat intakeMetabolismPathologyPathophysiologyAlkanesulfonatesAnimalsApolipoprotein E3Apolipoproteins EAtherosclerosisBiological MarkersBlood VesselsCell AdhesionCholesterolCholesterol, DietaryCollagenDietary FatsFemaleHypercholesterolemiaInflammationInsulin ResistanceLipidsLipoproteinsMacrophagesMiceMice, TransgenicMonocytesNF-kappa BPhenylpropionatesPPAR alphaPPAR gamma
TNO Identifier
239560
ISSN
10795642
Source
Arteriosclerosis, Thrombosis, and Vascular Biology, 26(11), pp. 2560-2566.
Pages
2560-2566
Files
To receive the publication files, please send an e-mail request to TNO Repository.